Departments of Chemistry; Molecular, Cellular and Developmental Biology; and Pharmacology, Yale University, New Haven, CT 06511 (USA).
Angew Chem Int Ed Engl. 2014 Feb 24;53(9):2312-30. doi: 10.1002/anie.201307761. Epub 2014 Jan 23.
Traditionally, biological probes and drugs have targeted the activities of proteins (such as enzymes and receptors) that can be readily controlled by small molecules. The remaining majority of the proteome has been deemed "undruggable". By using small-molecule modulators of the ubiquitin proteasome, protein levels, rather than protein activity, can be targeted instead, thus increasing the number of druggable targets. Whereas targeting of the proteasome itself can lead to a global increase in protein levels, the targeting of other components of the UPS (e.g., the E3 ubiquitin ligases) can lead to an increase in protein levels in a more targeted fashion. Alternatively, multiple strategies for inducing protein degradation with small-molecule probes are emerging. With the ability to induce and inhibit the degradation of targeted proteins, small-molecule modulators of the UPS have the potential to significantly expand the druggable portion of the proteome beyond traditional targets, such as enzymes and receptors.
传统上,生物探针和药物针对的是蛋白质(如酶和受体)的活性,这些活性可以通过小分子很容易地控制。剩下的大多数蛋白质组被认为是“不可成药的”。通过使用泛素蛋白酶体的小分子调节剂,可以靶向蛋白质水平,而不是蛋白质活性,从而增加可成药的靶标数量。虽然靶向蛋白酶体本身会导致蛋白质水平的全面增加,但靶向 UPS 的其他成分(例如,E3 泛素连接酶)可以更有针对性地增加蛋白质水平。或者,用小分子探针诱导蛋白质降解的多种策略正在出现。具有诱导和抑制靶向蛋白降解的能力,泛素蛋白酶体的小分子调节剂有可能显著扩大蛋白质组的可成药部分,超越传统的靶标,如酶和受体。